Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Legal Officer | April 28, 2020 | April 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date April 28, 2020 · Filed April 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 111,171 |
Ending reported balance
After 2020-04-29 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-04-28 · Exercise / conversion · Acquired 1,220 · Balance 112,391 Row 2 · 2020-04-28 · Sale · Disposed 1,220 · Balance 111,171 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2020-04-29 · Exercise / conversion · Acquired 3,780 · Balance 114,951 Row 4 · 2020-04-29 · Sale · Disposed 3,780 · Balance 111,171 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2027-07-13 | Direct | 44,413 |
Reported balance
After 2020-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-28 · Exercise / conversion · Disposed 1,220 · Balance 44,413 F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2027-07-13 | Direct | 40,633 |
Reported balance
After 2020-04-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-29 · Exercise / conversion · Disposed 3,780 · Balance 40,633 F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,139 | $99.68 | $113,535.52 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 12 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 3,528 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.44 to $100.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,976 | $98.75 | $293,880.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 11 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 4,667 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.23 to $99.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,357 | $97.88 | $230,703.16 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 10 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 7,643 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 287 | $100.75 | $28,915.25 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 9 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 3,240 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.57 to $101.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,139 | $99.68 | $113,535.52 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 8 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 3,527 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.44 to $100.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,977 | $98.75 | $293,978.75 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 7 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 4,666 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.23 to $99.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,357 | $97.88 | $230,703.16 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 6 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 7,643 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 05, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 5 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 05, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 05, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 05, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 05, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,737 Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:18 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 17,442 | $0.00 Strike: $94.47 | $0.00 |
DisclosureSEC source: 0001628280-19-010000 · wf-form4_156503988474607.xml · derivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,442 Underlying: COMMON STOCK · 17,442 shares Expires 2029-07-31 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:18 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantCOMMON STOCK | 5,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-010000 · wf-form4_156503988474607.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,737 Read SEC document |
| June 13, 2019 Filed Feb 12, 2020 16:22 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-001426 · wf-form5_158154253907937.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,171 Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 100 | $68.00 | $6,800.00 |
DisclosureSEC source: 0001628280-19-006596 · wf-form4_155752508961628.xml · nonDerivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,358 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 500 | $67.59 | $33,795.00 |
DisclosureSEC source: 0001628280-19-006596 · wf-form4_155752508961628.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,458 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 41,667 | $66.31 | $2,762,938.77 |
DisclosureSEC source: 0001628280-19-006596 · wf-form4_155752508961628.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,958 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.92 to $66.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 37,733 | $65.54 | $2,473,020.82 |
DisclosureSEC source: 0001628280-19-006596 · wf-form4_155752508961628.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,625 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.92 to $65.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 17:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,900 | $72.43 | $137,617.00 |
DisclosureSEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 6 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,358 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.29 to $72.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 17:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,702 | $71.40 | $478,522.80 |
DisclosureSEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 5 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,258 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.24 to $72.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 17:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 15,801 | $70.76 | $1,118,078.76 |
DisclosureSEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,960 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.24 to $71.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 17:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 35,300 | $69.64 | $2,458,292.00 |
DisclosureSEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,761 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.24 to $70.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 17:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 30,297 | $68.93 | $2,088,372.21 |
DisclosureSEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,061 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.24 to $69.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 12, 2019 Filed Apr 22, 2019 17:40 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,358 F1 · shares: These shares represent shares that the reporting person donated as a gift to a donor advised fund administered by the Deseret Trust Company. Read SEC document |
| December 10, 2018 Filed Feb 5, 2019 17:14 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 2,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-000973 · wf-form5_154940483860384.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,566 F1 · kind: Represents shares of Common Stock that the reporting person donated as a gift to a donor advised fund administered by the Deseret Trust Company. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 17:36 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionSERIES A PREFERRED STOCK · Derivative | 6,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012495 · wf-form4_153929374558330.xml · derivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 6,561 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 17:36 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 6,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012495 · wf-form4_153929374558330.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.